The latest from BioStock
» Toleranzia initiates tox study for drug candidate TOL2
» Lipum publishes important results in journal
» Aqilion targets eosinophilic esophagitis with AQ280
» BrainCool comments on the agreement with the University of Maryland
» CLS CEO on Q2 and upcoming milestones
Read BioStock's weekly newsletter for v.34 here.
See the company presentation presented by the CEO Anna Ljung!
Morning news
BrainCool announces that BrainCool System launched in seven new countries in Asia in collaboration with INCH. Read more.
Dicot has filed a new patent application with the U.S. Patent and Trademark Office. The application covers the new oral formulation of the candidate LIB-01. Read more.
Faron Pharmaceuticals has received orphan drug status from FDA - for Bexmarilimab. Read more.
FluoGuide reports additional positive interim data from phase IIa study with FG001 in head and neck cancer. Read more.
AstraZeneca will present 93 abstracts in the field of acute respiratory diseases at European Respiratory Society (ERS) International Congress 2023 in Milan, Italy on September 9-13, 2023. Read more.
Acarix announces that the first hospital within Veterans Affairs Healthcare System standardizes the use of CADScor System. Read more.
Ziccums vd Ann Gidner participates in analyst interviews. Read more.
Integral calls for an annual general meeting. Read more.
Reports
Elicera Therapeutics Faron Pharmaceuticals Inhalation Sciences Lipigon Pharmaceuticals Medim Mendus Redsense Medical
Communiqués
Change in equity and number of votes
News since Monday lunch
First patient has been included in Stayble Therapeutics clinical phase Ib study in herniated discs. Read more.
Clinical Laserthermia Systems American subsidiaries, CLS Americas, has entered into an agreement with Focalyx for joint sales of image-guided focal laser ablation of prostate cancer. Read more.
Toleranzia published a prospectus in connection with a rights issue of units. Read more.
Lytix Biopharma announced that patient recruitment to the company's LTX-135 study has been conducted. Read more.
FluoGuide has completed patient recruitment and treatment in the phase IIb study FG001 in aggressive brain cancer. Read more.
Home check has been conditionally approved for continued listing of Nasdaq and can complete the transaction with Cinema Vito's. Read more.
Cereno Scientific presented speakers and programs at the Capital Markets Day on August 30. Read more.
BrainCool commented on new scientific publications. Read more.
An article regarding the SARS-CoV-2 vaccine project being conducted by Marking and professor Mirazimi Wings has been published in the journal Vaccine. Read more.
Sobi published a prospectus regarding the rights issue. Read more.
Biosergen announced results in T02. Read more.
OncoZenge published shareholder Niclas Holmgren Proposal for the extraordinary general meeting on September 8. Read more.
The Knowledge Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attanas QCM technology. Read more.
Genmab will present at Morgan Stanley 21st Annual Global Healthcare Conference. Read more.
BioPorto informed about upcoming participation in conferences. Read more.
Pliant Therapeutics announced three presentations at European Respiratory Society International Congress 2023. Read more.
This morning's price development
Winner: Lipidor +16,55%, Cereno Scientific +11,57%, Asarina Pharma +10,75%, BPC Instruments +10,38%, Biosergen +9,82%
Förlorare: Xbrane Biopharma -39,97%, OptiCept Technologies -18,62%, Miris Holding -15,38%, QuiaPeg Pharmaceuticals -13,78%, Arcede Pharma -11,07%
Index: OMSX30 2185 +0,52%, Healthcare +0,20%
More from BioStock
» All the pieces in place for Dicot during Q2
» Invent Medic signs distribution agreement in Australia
» Scandion Oncology reports progress in Q2
» CombiGene's CEO gives a status update» Cereno's CEO on study progress during Q2
» Stayble Therapeutics' progress in the second quarter